Last update 19 Jun 2024

CD3/CD19 negative allogeneic hematopoietic stem cells(University of Pittsburgh)

Overview

Basic Info

Drug Type
Hematopoietic stem cell therapy
Synonyms-
Target
CD19 x CD3
Mechanism
CD19 modulators(B-lymphocyte antigen CD19 modulators), CD3 modulators(T cell surface glycoprotein CD3 modulators), Stem cell replacements
Therapeutic Areas
Immune System DiseasesCongenital DisordersEndocrinology and Metabolic Disease+ [2]
Active Indication-
Inactive Indication
Common Variable ImmunodeficiencyGranulomatous Disease, ChronicJob Syndrome+ [3]
Originator Organization
University of PittsburghUniversity of Pittsburgh
Active Organization-
Inactive Organization
University of PittsburghUniversity of Pittsburgh
Drug Highest PhasePendingPhase 1/2
First Approval Date-
Regulation-

Related

1
Clinical Trials associated with CD3/CD19 negative allogeneic hematopoietic stem cells(University of Pittsburgh)
NCT01852370 / Enrolling by invitationPhase 1/2IIT
Bilateral Orthotopic Lung Transplant in Tandem With CD3+ and CD19+ Cell Depleted Bone Marrow Transplant From Partially HLA-Matched Cadaveric Donors
100 Clinical Results associated with CD3/CD19 negative allogeneic hematopoietic stem cells(University of Pittsburgh)
Login to view more data
100 Translational Medicine associated with CD3/CD19 negative allogeneic hematopoietic stem cells(University of Pittsburgh)
Login to view more data
100 Patents (Medical) associated with CD3/CD19 negative allogeneic hematopoietic stem cells(University of Pittsburgh)
Login to view more data
100 Deals associated with CD3/CD19 negative allogeneic hematopoietic stem cells(University of Pittsburgh)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Common Variable ImmunodeficiencyPhase 2
US
University of PittsburghUniversity of Pittsburgh
20 Jun 2013
Granulomatous Disease, ChronicPhase 2
US
University of PittsburghUniversity of Pittsburgh
20 Jun 2013
Job SyndromePhase 2
US
University of PittsburghUniversity of Pittsburgh
20 Jun 2013
Mendelian susceptibility to mycobacterial diseasePhase 2
US
University of PittsburghUniversity of Pittsburgh
20 Jun 2013
Severe Combined ImmunodeficiencyPhase 2
US
University of PittsburghUniversity of Pittsburgh
20 Jun 2013
Wiskott-Aldrich SyndromePhase 2
US
University of PittsburghUniversity of Pittsburgh
20 Jun 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free